- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Allergan’s Viberzi (eluxadoline) now available in the US
15 December 2015 • Author: Victoria White
Allergan’s Viberzi (eluxadoline) is now available by prescription in the US.
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D).
“We are excited about the launch of Viberzi, which addresses an unmet need among IBS-D patients seeking a treatment to manage their symptoms proactively,” said William Meury, President and Executive Vice President, Branded Pharma at Allergan. “This introduction reaffirms Allergan’s commitment to providing a new treatment option that serves to help gastroenterologists reach better outcomes for their patients.”
IBS-D is a multifactorial disorder marked by recurrent abdominal pain or discomfort and diarrhoea that affects as many as 15 million adult Americans, impacting both women and men equally. There are few prescription treatment options available for IBS-D, particularly options that relieve both the diarrhoea and abdominal pain associated with IBS-D.
Viberzi maintained symptom relief throughout treatment in trials
Viberzi has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist. It relieves the core symptoms of IBS-D, diarrhoea and abdominal pain. Symptom relief was maintained throughout treatment in two pivotal clinical trials.
On 12 November 2015, the US Drug Enforcement Agency (DEA) completed its review of Viberzi (eluxadoline), and published its Final Rule placing Viberzi into Schedule IV of the Controlled Substance Act. Schedule IV drugs, substances, or chemicals are defined by the DEA as drugs with a low potential for abuse and low risk of dependence.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics